ReviewFrontiers in pharmacology2018
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05044936 (The Effects of Topical Cannabidiol Cream on Post-exercise Recovery), which is not on this map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Topical Cannabidiol Cream on Post-exercise Recovery
Who cites it
70 citing papers in PubMed, 164 citations in OpenAlex.
- Effects of Oral Cannabidiol on Health and Fitness in Healthy Adults: An 8-Week Randomized Trial.Nutrients · 2023Trial
- Trial
- Plant-derived neuroprotective compounds and nanoformulations targeting Parkinson's disease: a semi-systematic review of mechanisms and therapeutic potential.Metabolic brain disease · 2026Review
- Electroretinographical analysis of the effect of cannabidiol (CBD) in eyes of Zucker diabetic fatty rats.Journal of cannabis research · 2026Article
- Dietary Cannabidiol Supplementation on Growth Performance, Behavior, Blood Profile, Metabolomic Analysis, and Fatty Acid Composition in Rabbits: A Multi-Disciplinary Approach to Improve Welfare and Productivity.Veterinary sciences · 2025Article
- Malaria parasite cysteine and aspartic proteases as key drug targets for antimalarial therapy.Journal of molecular modeling · 2025Review
- Preventive beneficial effects of cannabidiol in a reserpine-induced progressive model of parkinsonism.Frontiers in pharmacology · 2025Article
- Review
- Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review.Journal of gastroenterology and hepatology · 2024Review
- FDA-approved cannabidiol [EpidiolexMilitary Medical Research · 2024Article
- Unraveling the Mechanisms of Cannabidiol's Pharmacological Actions: A Comprehensive Research Overview.Topics in current chemistry (Cham) · 2024Review
- Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review.Neuropsychopharmacology reports · 2024Review
- Metallothionein Family Proteins as Regulators of Zinc Ions Synergistically Enhance the Anticancer Effect of Cannabidiol in Human Colorectal Cancer Cells.International journal of molecular sciences · 2023Article
- Cannabinoids for painful dystonia in corticobasal syndrome: a report of three patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans.Neurochemical research · 2023Article
- The therapeutic potential of purified cannabidiol.Journal of cannabis research · 2023Review
- Cannabidiol as a Promising Therapeutic Option in IC/BPS: In Vitro Evaluation of Its Protective Effects against Inflammation and Oxidative Stress.International journal of molecular sciences · 2023Article
- The Effects of Cannabidiol on the Driving Performance of Healthy Adults: A Pilot RCT.AJPM focus · 2023Article
- Total Phenolic Content and Antioxidant Activity of In Vitro Digested Hemp-Based Products.Foods (Basel, Switzerland) · 2023Article
- Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies.Pharmaceuticals (Basel, Switzerland) · 2023Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Movement disorders such as Parkinson's disease and dyskinesia are highly debilitating conditions linked to oxidative stress and neurodegeneration. When available, the pharmacological therapies for these disorders are still mainly symptomatic, do not benefit all patients and induce severe side effects. Cannabidiol is a non-psychotomimetic compound from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.